How to Justify Study Continuation After Significant Deviations
In the pharmaceutical industry, deviations during stability studies can challenge the integrity of your data and call into question the continuation of the study. Regulatory authorities such as the USFDA expect firms to assess whether the deviation significantly impacts product quality or study reliability. This guide outlines a structured, risk-based approach to justify the continuation…
Read More “How to Justify Study Continuation After Significant Deviations” »